Study of Droxidopa in Patients With Neurologic Hypotension
droxidopa
Autonomic Nervous System Diseases+19
+ Basal Ganglia Diseases
+ Brain Diseases
Treatment Study
Summary
Study start date: March 1, 1999
Actual date on which the first participant was enrolled.PROTOCOL OUTLINE: Patients receive escalating doses of droxidopa or placebo for 7-14 days. Patients undergo blood pressure measurements hourly in both supine and standing positions.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.Treatment Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.Over 20 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- Orthostatic hypotension due to autonomic nervous system failure Fall in systolic blood pressure (supine to standing) of at least 20 mm Hg and diastolic blood pressure of at least 15 mm Hg AND Symptoms of hypotension such as dizziness, light-headedness, unsteadiness, dimming or blurred vision History of syncope or near-syncope --Prior/Concurrent Therapy-- Endocrine therapy: No concurrent adrenergics Concurrent fludrocortisone allowed Other: Concurrent indomethacin, support garments, and high salt diets allowed
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location
New York University School of Medicine
New York, United StatesOpen New York University School of Medicine in Google Maps